These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23568475)

  • 1. Computational models for tuberculosis drug discovery.
    Ekins S; Freundlich JS
    Methods Mol Biol; 2013; 993():245-62. PubMed ID: 23568475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informatics resources for tuberculosis--towards drug discovery.
    Sundaramurthi JC; Brindha S; Reddy TB; Hanna LE
    Tuberculosis (Edinb); 2012 Mar; 92(2):133-8. PubMed ID: 21943870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets.
    Ekins S; Freundlich JS
    Pharm Res; 2011 Aug; 28(8):1859-69. PubMed ID: 21547522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico analyses for the discovery of tuberculosis drug targets.
    Chung BK; Dick T; Lee DY
    J Antimicrob Chemother; 2013 Dec; 68(12):2701-9. PubMed ID: 23838951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.
    Sarker M; Talcott C; Madrid P; Chopra S; Bunin BA; Lamichhane G; Freundlich JS; Ekins S
    Pharm Res; 2012 Aug; 29(8):2115-27. PubMed ID: 22477069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
    Christophe T; Ewann F; Jeon HK; Cechetto J; Brodin P
    Future Med Chem; 2010 Aug; 2(8):1283-93. PubMed ID: 21426019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
    Ioerger TR; Sacchettini JC
    Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.
    Ekins S; Freundlich JS; Choi I; Sarker M; Talcott C
    Trends Microbiol; 2011 Feb; 19(2):65-74. PubMed ID: 21129975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities in tuberculosis drug discovery: an industry perspective.
    Shirude PS; Ramachandran S; Hosagrahara V
    Future Med Chem; 2013 Apr; 5(5):499-501. PubMed ID: 23573967
    [No Abstract]   [Full Text] [Related]  

  • 11. Improving the tuberculosis drug development pipeline.
    Evangelopoulos D; McHugh TD
    Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of new 1,3,5-triazine scaffolds with potent activity against Mycobacterium tuberculosis H37Rv.
    Sunduru N; Gupta L; Chaturvedi V; Dwivedi R; Sinha S; Chauhan PM
    Eur J Med Chem; 2010 Aug; 45(8):3335-45. PubMed ID: 20452706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening.
    Segura-Cabrera A; Rodríguez-Pérez MA
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3152-7. PubMed ID: 18486472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.
    Guillemont J; Meyer C; Poncelet A; Bourdrez X; Andries K
    Future Med Chem; 2011 Sep; 3(11):1345-60. PubMed ID: 21879841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current challenges in drug discovery for tuberculosis.
    Kumar A; Chettiar S; Parish T
    Expert Opin Drug Discov; 2017 Jan; 12(1):1-4. PubMed ID: 27797593
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges and opportunities in developing novel drugs for TB.
    Kaneko T; Cooper C; Mdluli K
    Future Med Chem; 2011 Sep; 3(11):1373-400. PubMed ID: 21879843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?
    Goldman RC
    Tuberculosis (Edinb); 2013 Nov; 93(6):569-88. PubMed ID: 24119636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tuberculosis: a glimpse of promising drug targets.
    Arora N; Banerjee AK
    Mini Rev Med Chem; 2012 Mar; 12(3):187-201. PubMed ID: 22356190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.
    Ekins S; Freundlich JS; Hobrath JV; Lucile White E; Reynolds RC
    Pharm Res; 2014 Feb; 31(2):414-35. PubMed ID: 24132686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.